We have located links that may give you full text access.
Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma.
A retrospective study was performed to evaluate the results of dermatologic radiotherapy in a large series of patients affected by primary cutaneous B-cell lymphomas. The study included 104 patients with cutaneous follicle center cell lymphoma treated with orthovoltage radiotherapy from 1973 to 2000. The total doses ranged from 14 to 35 Gy (mean 23.55 Gy). Results regarded 102 patients (mean follow-up 65.08 months). Complete remission was observed in all cases; 76 patients experienced a relapse after a mean interval of 22.03 months following radiotherapy, with a relapse-free rate of 22.82 % after 5 years. Extracutaneous progression was observed in 9 cases (8.82 %). An overall actuarial survival rate of 97.36 % was observed after 5 years. A salvage treatment of relapses brought 44 cases to remission. Although we have observed a relapse-free rate lower than that reported by others, dermatologic radiotherapy was "curative" in 25.49 % of cases. Such treatment appears particularly useful in the cases with few lesions and in the management of new cutaneous localizations of follicular center cell lymphoma.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app